Arvin joined Mersana in November 2020, bringing deep experience in leading early-stage trials and late-stage global registrational trials. Prior to joining Mersana, Arvin spent over a decade at Bristol Myers Squibb in various roles with increasing responsibility for the clinical development of hematology and oncology including immuno-oncology therapies. Most recently, he was Vice President and Head of Clinical Hematology. Before that, he was Vice President and Development Lead for Melanoma and GU cancers, and played a critical role in the global approval of nivolumab and nivolumab plus ipilimumab combinations in a number of indications. Earlier, he was responsible for the nivolumab and ipilimumab life-cycle clinical development plans including those in gynecological cancers. Finally, he has held leadership roles overseeing a pipeline of early clinical programs as well as roles in medical affairs.  

Dr. Yang received his M.D. and Ph.D. from Rutgers Robert Wood Johnson Medical School and completed training in internal medicine at Beth Israel Deaconess, Harvard Medical School and in oncology at Memorial Sloan-Kettering Cancer Center.